Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Myoepithelium assessment with p63 immunostaining in formalinfixed paraffin-embedded breast cancer tissue pre-treated with RNA-later

  • Anna Ehinger
  • Inger Remse
  • Kristina Lövgren
  • Cecilia Hegardt
  • Jari Häkkinen
  • Lao Saal
  • Johan Vallon-Christersson
  • Åke Borg
Publishing year: 2017-09-02
Language: English
Pages: 299-299
Publication/Series: Virchows Archiv
Volume: 471
Issue: Supplement 1
Document type: Conference paper: abstract
Publisher: Springer

Abstract english

Objective: To assessmyoepithelium with p63 in fresh breast cancer (BC)
tissue samples collected in RNA later for further analysis with Next
Generation Sequencing (NGS) technique. For a better understanding of
the NGS bulk-analysis, a central part of the sample in RNA-later is
formalin-fixed paraffin-embedded to score relative cellularity in % on
hematoxylin-eosin (HE) staining (% of invasive cancer, cancer in situ,
benign epithelium, lymphocytes and fat). Our aim is hence to test p63
immunohistochemistry (IHC) to highlight myoepithelium and to facilitate
the evaluation of the relative cellularity on BC-tissue pre-treated with
Method: Two-hundred and twenty-four selected samples of fresh BC
tissue collected in RNA-later. A 10 mg central piece from each sample
was FFPE and assembled in a tissue-microarray (TMA) and sectioned to
HE and p63 IHC.
Results: All samples (n = 224) had internal control for myoepithelium
surrounding in situ cancer or benign epithelium. p63 showed positive
nuclear staining in myoepithelial cells in 92 % (206/224) of samples
and false negative p63 staining in 8 % (18/224).
Conclusion: p63 IHC is assessable in samples of FFPE BC-tissue pretreated
with RNA-later.


  • Cancer and Oncology


29th European Congress of Pathology
  • Personalized Breast Cancer Treatment
  • The Liquid Biopsy and Tumor Progression in Breast Cancer
  • Translational Oncogenomics
  • Familial Breast Cancer
  • ISSN: 1432-2307
Åke Borg
Åke Borg
E-mail: ake [dot] borg [at] med [dot] lu [dot] se

Principal investigator

Oncology and Pathology, MV

+46 46 275 25 52

MV 404 C21B2


Project manager

Familial Breast Cancer



Oncology and Pathology, MV

MV 404 C21C2